TET2 and cyclic hematopoiesis: Analysis of the CANTOS randomized controlled trial showed that the use of canakinumab (an anti–IL-1β monoclonal antibody) in individuals with TET2-driven CH resulted in reduced major adverse cardiovascular events and improved anemia of inflammation (Svensson et al., 2022; Woo et al., 2023).